SCYNEXIS Inc (SCYX) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 11 from a previous price target of $15 . RBC Capital Mkts advised their Clients and Investors in a research report released on Mar 3, 2017.
Based on several research reports , Shares were Reiterated by RBC Capital Mkts on Mar 3, 2017 to “Outperform” and Lowered the Price Target to $ 11 from a previous price target of $15 .Shares were Reiterated by RBC Capital Mkts on Mar 3, 2017 to “Outperform” and Lowered the Price Target to $ 11 from a previous price target of $15 .
Several company insiders have filed Insider transactions , on Dec 22, 2016, Marco Taglietti (CEO) purchased 25,000 shares at $3.30 per share price. According to the SEC, on Dec 19, 2016, Gonzalez David Angulo (Chief Medical Officer) purchased 4,000 shares at $3.25 per share price. On Sep 16, 2016, Patrick Machado (director) purchased 40,000 shares at $2.94 per share price, according to the Form-4 filing with the securities and exchange commission.
SCYNEXIS Inc opened for trading at $3.42 and hit $3.4699 on the upside on Monday, eventually ending the session at $3.43, with a gain of 0.88% or 0.03 points. The heightened volatility saw the trading volume jump to 1,91,344 shares. Company has a market cap of $82 M.
SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.